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ABSTRACT Platelets release specific growth factors that
stimulate division of aortic endothelial cells. Acidification or
heating to 560C of platelet extracts is required to detect these
factors. Nonheated platelet extracts inhibit endothelial growth.
To determine if this inhibitory effect is due to a discrete
chemical substance, a crude extract obtained by freezing and
thawing human platelets was incubated with an endothelial cell
mitogen and found to inhibit the endothelial cell incorporation
of [3Hjthymidine by greater than 95%. The inhibitor was
partially purified by ion-exchange and gel-riltration chroma-
tography. The partially purified material inhibited endothelial
cell division as well as DNA synthesis. Inhibition caused by
the partially purified material was concentration dependent,
reversible, and not due to cytotoxicity. Further purification
by heparin-Sepharose chromatography resulted in removal
of >95% of the contaminating substances without a loss of
inhibitory activity. Physical characterization revealed that
heparin-Sepharose-purifi'ed factor was heat labile, had a mo-
lecular size estimated at 3540 kDa, and was stable between pH
4.5 and 9.0. Treatment with proteolytic enzymes destroyed all
biologic activity, suggesting a peptide composition. These data
support the conclusion that platelets contain a potent inhibitor
of endothelial replication and growth. Since platelet deposition
and release occur after endothelial denudation, release of this
platelet-derived growth inhibitor may be an important regu-
lator of reendothelialization that occurs after vessel injury.
Specific growth factors have been purified from platelets that
stimulate division of smooth muscle cells (1, 2), endothelial
cells (3, 4), and fibroblasts (2, 5). The role of platelet-derived
growth factors following endothelial injury in vivo has re-
mained undefined, since crude platelet extracts must be
subjected to nonphysiologic conditions to purify a given
factor and since insufficient quantities ofthese materials have
been available for in vivo testing. Our laboratory has reported
the presence of an endothelial mitogen in extracts of human
platelets (3). During the preparation of these extracts, it was
noted that the mitogen could only be detected after the
extract was heated to 56°C or acidified to below pH 4.0. Since
the unheated platelet extracts actually inhibited endothelial
cell replication, we undertook the present studies to deter-
mine whether the inhibitory activity was a discrete chemical
substance and, if so, to determine some of its physicochemi-
cal properties.
MATERIALS AND METHODS
Isolation of Endothelial Cells. Porcine aortic endothelial
cells were isolated as described (6). After incubating aortas
from young piglets for 30 min at 37°C in Dulbecco's modified
Eagle's medium (DMEM; Flow Laboratories) containing
0.1% type II collagenase (Worthington, lot 42C074; 126
units/mg), detached endothelial cells were cultured in 10-cm
dishes (Falcon) in DMEM supplemented with 20% (vol/vol)
bovine serum (Colorado Serum, Denver, CO). After allowing
sufficient time (6-8 hr) for attachment, this medium was
removed and replaced with DMEM supplemented with 10%
(vol/vol) citrated human plasma (16 mM sodium citrate/7
mM citric acid, pH 7.4; the American Red Cross) prepared as
described (3). The cells were maintained in this medium until
confluent growth was reached (usually 7-8 days). The cells
were then removed with 0.1% trypsin/0.02% EGTA
(GIBCO) and cultured using a 1:3 passage dilution. This
procedure was repeated every 7-10 days to avoid long
periods of confluent growth. Cells processed in this manner
formed a homogeneous monolayer, had no myofilaments by
electron microscopy, and stained for factor VIII-related
antigen (7). No observable transformation or loss of the
endothelial monolayer (8, 9) was noted for up to 6 weeks.
[3H]Thymidine Incorporation into Cultured Endothelial
Cells. To quantitate DNA synthesis, porcine endothelial cells
were cultured in microtest wells (Falcon) at 5000 cells per
well in DMEM containing 10% (vol/vol) citrated human
plasma. After 16 hr, the medium was removed and replaced
with DMEM/2% (vol/vol) human platelet-poor plasma (PPP)
(final volume, 200 ,l). The PPP was prepared by a described
method (3). After 3 days, the platelet extract or chromato-
graphic fraction to be tested was added directly to duplicate
wells with 0.5 ,uCi of [3H]thymidine (10 Ci/mmol; 1 Ci = 37
GBq) (Schwartz/Mann). To determine the effect ofinhibitory
material, the cultures were maximally stimulated with either
10% (vol/vol) human serum or 1.0 ,ug of partially purified
platelet-derived endothelial mitogen per ml that had been
purified by a published method (3). Test mixtures were
incubated for 36 hr in a humidified incubator containing an
atmosphere of 5% C02/95% air at 37°C. Following termina-
tion of the experiment, the wells were washed twice with
Ringer's bicarbonate, pH 7.4, at 4°C and precipitated twice
(10 min each) with 5% (wt/vol) trichloroacetic acid. Follow-
ing DNA extraction with two 0.2-ml aliquots of 0.1 M
NaOH/1% (wt/vol) NaDodSO4, the radioactivity incorpo-
rated into DNA was determined by liquid scintillation count-
ing.
Purification of Platelet-Derived Growth Inhibitor. Six out-
dated 10-unit platelet packs (American Red Cross) were
combined, washed thoroughly with 0.15 M NaCl/0.01 M
Na2HPO4, pH 7.4, and centrifuged at 5000 x g for 15 min to
remove the residual plasma. The platelet pellet was resus-
pended in 2 vol of 0.01 M Na2HPO4/0.9 M NaCl, pH 7.4, and
freeze/thawed three times. After centrifuging the mixture at
20,000 x g for 30 min, the supernatant was delipidated by
filtration through Whatman no. 1 paper. The filtrate was
dialyzed against 4 liters of 0.01 M Na2HPO4, pH 7.4, for 24
Abbreviations: PDECM, platelet-derived endothelial cell mitogen;
PDGI, platelet-derived growth inhibitor; PPP, platelet poor plasma;
PDGF, platelet-derived growth factor.
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hr with 2 changes then stirred with 1.0 g of DEAE-Sephadex
beads (Sigma) at 40C for 24 hr. A column (5 x 10 cm) was
poured and washed with two column volumes of 0.01 M
(NH4)2CO3, pH 7.4. The column was eluted with 0.01 M
(NH4)2CO3/1.0 M NaCl, pH 7.4, and the fractions were
assayed for inhibitory activity in the presence of partially
purified platelet-derived endothelial cell mitogen (PDECM)
and 2% (vol/vol) human PPP (3). Biologically active platelet-
derived growth inhibitor (PDGI)-containing material ob-
tained from the two most active fractions was dialyzed using
Spectropor 3 membranes (Spectrum Medical Industries, Los
Angeles, molecular weight cutoff 3500) for 18 hr against 0.01
M (NH4)2CO3, pH 7.4, and concentrated 5-fold by lyophiliza-
tion. The concentrated material (1.2 ml) was applied to a
Sephadex G-150 (Sigma) column (160 x 1.2 cm) that had been
equilibrated with 0.01 M (NH4)2CO3, pH 7.4, and eluted with
the same buffer at a flow rate of 14 ml/hr. The column had
been calibrated using bovine serum albumin, cytochrome c,
and ovalbumin (Sigma). Fractions (5 ml) were collected, and
10 Al of each fraction was assayed for its capacity to inhibit
[3H]thymidine incorporation.
The PDGI was also further purified by heparin-Sepharose
chromatography. Protein (3.5 mg) was dialyzed against 0.1 M
(NH4)2C03, pH 7.4, for 18 hr at 40C then applied to a 10 x 0.3
cm column containing heparin-Sepharose that was a gift from
M. Griffith. The column was washed with two column
volumes of the equilibration buffer and eluted using a step
gradient from 0.1 to 1.5 M NaCl. The 2.5-ml fractions were
tested directly for PDGI bioactivity.
Other Mitogens and Cell Types. Platelet-derived growth
factor (PDGF) was prepared as described (10). BALB/c 3T3
cells (clone A31) were a gift from W. J. Pledger. Smooth
muscle cells were isolated from porcine aortas (11). DNA
synthesis in each of these cell types was quantitated by
plating the cells at a density of 5000 cells per well in 96-well
microtest plates (Falcon) in either Eagle's minimal essential
medium (MEM) plus 10% (vol/vol) bovine serum (fibro-
blasts) or DMEM plus 10%6 (vol/vol) fetal bovine serum
(smooth muscle cells). After 5 days of incubation the medium
was removed and replaced with fresh medium containing 2%
(vol/vol) PPP, 0.5 ,Ci [3H]thymidine and test reagents. After
a 36-hr (fibroblasts) or a 30-hr (smooth muscle cells) incuba-
tion, [3H]thymidine incorporation was determined.
Determination of Growth Velocity. To determine the rate of
growth, the porcine endothelial cells were plated at 6-7000
cells per well in 24-multiwell plates (Falcon) in DMEM
supplemented with 10% (v6l/vol) human citrated plasma (2).
The medium was changed after allowing 14 hr for attachment
and replaced with DMEM supplemented with 3% (vol/vol)
human PPP. Various test reagents were added to triplicate
wells, and the incubation was continued for 72 hr. At that
time cell number was determined by detaching the cells with
0.1% trypsin/0.02% EDTA and counting them in a particle
data counter (Coulter model ZBI). The remaining wells
received fresh medium with test reagents and were incubated
for an additional 72 hr before the procedure was repeated.
Assessment of Physical Properties of the PDGI. To deter-
mine temperature stability partially purified (DEAE-Seph-
adex) inhibitor was heated to 56°C for 1 or 2 hr or 100°C for
10 min. To determine if the inhibitor was susceptible to
proteolysis, an aliquot was incubated with a protease prep-
aration attached to CM-Sephadex beads (Sigma) at 37°C for
various times (0.5, 1, 2, and 4 hr). At those times the
preparation was centrifuged 3000 x g for 2 min, and the
supernatant was removed and tested for inhibitory activity.
Control tubes that did not contain the inhibitor and inhibitor
controls that did not contain protease-CM-Sephadex were
included for each time point. To exclude the possibility that
the active inhibitory material was a type of hepanin, material
that had been purified by heparin-Sepharose chromatography
was incubated with Flavobacterium heparinase (10 units/ml,
Sigma) for 1 hr at 370C and then added directly to test cultures
to determine if the inhibitory activity had been destroyed.
To determine if the inhibitory activity was due to a
proteolytic enzyme, crude platelet freeze/thaw supernatant
and DEAE-Sephadex- and heparin-Sepharose-purified inhib-
itor were tested for proteolytic activity using Bio-Rad
protease-substrate gel tablets. The test samples were added
at concentrations that were 10- to 100-fold greater than that
required to achieve maximal inhibition in the bioassay and
incubated at 220C for 24 hr. The results were compared to
trypsin standards.
RESULTS
Biological Activity of the PDGI. Crude freeze/thaw extracts
contained material that when incubated with quiescent
endothelial monolayers in the presence of 2% (vol/vol) PPP
and a highly purified preparation of the PDECM inhibited
[3H]thymidine incorporation (3). Partially purified (through
the DEAE step) PDGI retained the inhibitory activity.
Increasing concentrations of the DEAE-step material in-
duced an increased degree of inhibition that was maximal at
8 pg/ml (Fig. 1). In an additional experiment a concentration
of 8 ,g of partially purified inhibitor per ml reduced the effect
of 10% (vol/vol) human serum on [3H]thymidine incorpo-
ration into endothelial cultures by 85% (data not shown). To
exclude the possibility that this inhibition was simply due to
cytotoxicity, a lower concentration of'the inhibitor (2 ,tg/ml)
was incubated with various concentrations of PDECM. The
inhibitory effect could be partially overcome by adding
sufficient mitogen (Fig. 2, Left) so that PDECM at 1.0 ,ug/ml
could stimulate the rate of DNA synthesis to 76% of the
maximal rate of DNA synthesis. To determine if transient
exposure to the inhibitor resulted in a sustained inhibition,
endothelial cultures were exposed to the inhibitor transiently
for various periods of time from 2 to 31 hr (Fig. 2, Right).
Following inhibitor removal, the cultures were exposed to
PDECM'plus 2% (vol/vol) PPP, and the incubation was









FIG. 1. Inhibition of [3H]thymidine incorporation by a platelet-
derived factor. Various concentrations of partially purified PDGI
were added to quiescent endothelial nmonolayers growing in 1.0 pg of
PDECM per ml, 0.2 ml of DMEM, 2% (vol/vol) PPP, and 0.5 ,Ci
[3H]thymidine. Following a 36-hr incubation, the cells were precip-
itated twice with 5% (wt/vol) trichloroacetic acid, and the DNA was
extracted with 0.1 NaOH/1% NaDodSO4. The [3H]thymidine that
was incorporated into DNA was determined by liquid scintillation
counting.
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FIG. 2. Reversibility of the inhibitory effect of PDGI. Various
concentrations of PDECM were added to quiescent cells cultured in
PDGI (1.5 Zg/ml), 0.2 ml of DMEM, 2% (vol/vol) PPP, and 0.5 gCi
[3H]thymidine (Left). After a 36-hr incubation [3H]thymidine incor-
poration into DNA was determined as for Fig. 1. Control cultures
received the concentration ofPDECM listed plus 3% (vol/vol) PPP,
and the results are expressed as the percentage of maximum
[3H]thymidine incorporation at each concentration. In a separate
experiment (Right), quiescent endothelial monolayers were tran-
siently exposed to PDGI (4 gg/ml) in 0.2 ml ofDMEM. At the times
listed, the medium was aspirated, the cultures were washed twice
with phosphate-buffered saline, and 0.2 ml of DMEM containing
PDECM (0.4 u±g/ml) and 3% (vol/vol) PPP, and 0.5 gCi
[3H]thymidine was added. Following an additional 36-hr incubation
[3H]thymidine incorporation was determined. The results are pre-
sented as the mean ± 1 SD of the percent of maximal [3H]thymidine
incorporation that could be stimulated in control cultures receiving
serum-free DMEM for each of the times listed.
hr had no effect. An interval of 14 hr resulted in maximal
inhibition (39%), and exposure for longer intervals allowed
some restoration ofthe rate ofDNA synthesis toward control
levels (e.g., 14% inhibition at 31 hr). This restoration ap-
peared to be due to degradation of PDGI. When medium
containing inhibitor that had been incubated with cells for 31
hr was added to fresh endothelial cultures, its capacity to
inhibit [3H]thymidine incorporation was reduced by 55%
(data not shown).
To determine if the inhibitor could influence mitogenesis,
endothelial cells were cultured at a density of 6000 cells per
well in DMEM containing 10% (vol/vol) human citrated
plasma. Following a 14-hr incubation to allow for attachment,
the medium was aspirated and replaced with fresh DMEM
containing either PPP alone or PPP in combination with
PDECM with or without PDGI. Cell number doubled every
58 hr in the PDECM-exposed wells, whereas those exposed
to inhibitor showed only a minimal increase (Fig. 3). In a
separate experiment, an identical concentration of the inhib-
itor that had been heated to 560C for 2 hr was shown to have
no effect.
To obtain PDGI of higher purity, DEAE-Sephadex-pu-
rified inhibitor was further purified using heparin-Sepharose
chromatography. The biologic activity was eluted with 1 M
NaCl, and several contaminant peaks were removed (Fig. 4).
To determine the effect of the inhibitor on other cell types,
cultures of porcine aortic smooth muscle cells or BALB/c
3T3 fibroblasts were exposed to either PDGF plus PPP or
human serum plus various concentrations of inhibitor. Crude
preparations of PDGI (DEAE-Sephadex purified) reduced
[3H]thymidine incorporation that had been stimulated by
either human serum or PDGF in each of these cell types.
Following heparin-Sepharose chromatography, however, the
effect ofthe inhibitor was specific for endothelial cells and did














FIG. 3. Inhibition of endothelial cell growth by PDGI. Porcine
endothelial cells were plated at a density of 6000 cells per well in
DMEM containing 10%o (vol/vol) citrated human plasma. After
allowing 14 hr for attachment, the medium was removed, and fresh
DMEM containing PDECM (0.5 Ig/ml) plus 3% (vol/vol) PPP (A);
PDECM (0.5 ,ug/ml), PDGI (2.0 ,ug/ml) plus 3% (vol/vol) PPP (o);
or 3% (vol/vol) PPP alone (e) was added in a final volume of 0.75 ml.
After a 72-hr incubation, the cell number was determined in triplicate
cultures. The remaining cultures received fresh medium, and after 3
days the cell number was again determined in triplicate cultures. In
a separate experiment (Insert), the endothelial cultures were plated
in an identical manner but received PDECM (0.5 ,±g/ml) plus 3%
(vol/vol) PPP (A); PDECM (0.5 pg/ml), 3% (vol/vol) PPP, and PDGI
(m) that had been heat inactivated (56TC for 2 hr); or 3% (vol/vol) PPP
alone (o). Cell number was determined as described above.
Physical Properties of PDGI. Material that had been puri-
fied through the heparin-Sepharose step was subjected to
several physicochemical treatments to determine its proper-
ties (Table 1). The material was heat labile, and its inhibitory
activity was destroyed by boiling for 10 min or heating to 56TC
for 2 hr. Incubation for 4 hr in 0.01 M Na2HPO4, pH 7.4, at
37TC, however, resulted in no loss of activity. It appeared to
have a net negative charge, since it adhered to DEAE- but not
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FIG. 4. Heparin-Sepharose chromatography of the inhibitor.
Protein (2.5 mg) that had been retained on the DEAE-Sephadex was
dialyzed against 0.01 M (NH4)2CO3 (pH 7.4) then applied to a 10 x
0.3 cm heparin-Sepharose column. The column was washed with two
column volumes of the loading buffer and eluted with a step gradient
from 0.1 to 1.5 M NaCl. The inhibitory activity of each fraction was
determined as in Fig. 5. The hatched peaks denote the fractions
containing biologically active PDGI.
Cell Biology: Brown and Clemmons
3324 Cell Biology: Brown and Clemmons




PDGI (4.0 p.g/ml) + PDECM (0.5
AgIml)t 9
Heated PDGI (560C, 1 hr) 54
Heated PDGI (560C, 2 hr) 93
Heated PDGI (370C, 2 hr) 71
Heated PDGI (100TC, 10 min) 110
Exposure to pH 4.5 90
Exposure to pH 9.0 99
Exposure to protease (2 hr, 370C) 96
Exposure to protease (2 hr, 240C) 29
Exposure to protease + 0.02% EGTA
(2 hr, 170C) 13
Exposure to Flavobacterium heparinase
(10 units/ml, 1 hr, 370C) 16
*All preparations were tested in the presence of control medium
containing 2% (vol/vol) PPP and PDECM (0.5 Ag/ml).
tAll PDGI preparations tested had been purified by DEAE-Sephadex
and heparin-Sepharose chromatography.
rial showed that it was stable over a sharp range between pH
4.5 and 9.0. It appeared to be a peptide, since there was a
progressive loss ofinhibitory activity during a 2-hr incubation
at 37°C with protease attached to CM-cellulose. Control
incubations pf the inhibitor with this protease preparation at
23°C or at 379C in the presence of 0.02% EGTA resulted in
only minimal losses of inhibitory activity. Following expo-
sure to Flavobacterium heparinase for 1 hr at 370C, there was
no loss of inhibitory activity.
To exclude the possibility that the effect of the inhibitor
was due to proteolysis of growth factors, crude platelet
freeze/thaw lysate and DEAE-Sephadex- and heparin-Seph-
aroseApurified material were analyzed for proteolytic activi-
ty. Although ,the crude lysate contained proteolytic activity
equivalent to 2.5 p'g of trypsin per ml, DEAE-Sephadex-
purifled material had no detectable proteolytic activity using
a concentration that was 10-fold greater than that required for
maximal inhibition in the endothelial bioassay test system,
and heparin-Sepharose-purified material had no activity us-
ing a 100-fold excess.
To obtain a preliminary estimate of the molecular size of
the inhibitor, DEAE-purified PDGI was chromatographed on
Sephadex G-150 in 0.01 M (NH4)2CO3, pH 7.4. The bioactiv-
ity migrated with a distribution coefficient (Kd) of approxi-
mately 0.55 and had an estimated molecular weight of 37,000
(Fig. 5). Material of this purity retained full biologic activity
if stored at -70°C; however, if stored at -20°C, a progressive
loss of material occurred over a 3-month period.
DISCUSSION
The results of this study provide evidence that an inhibitor of
porcine endothelial cell DNA synthesis and growth is present
in human platelets. This material can be detected in platelet
supernatants after the freeze/thaw treatment indicating that
degranulation results in its release. The factor is heat labile,
anionic, and appears to be a peptide that is stable over a sharp
pH range from pH 4.5 to 9.0. Following further purification,
the factor has been shown to have a molecular weight of
-37,000 and to be stable for 2 hr at 37°C. The addition of
various concentrations of the partially purified material
results in a concentration-dependent inhibition of porcine
endothelial cell replication. In summary, it appears that the
freeze/thaw procedure results in the release of a peptide that
inhibits endothelial cell replication.
92 kDa





FIG. 5. Gel-filtration chromatography ofPDGI. Material (6.0 ml)
that had been eluted from the DEAE-Sephadex column was con-
centrated to 1.6 ml and applied to a 1.6 x 95 cm Sephadex G-150
column that had been equilibrated in 0.01 M (NH4)2CO3, pH 7.4. The
column was eluted at a flow rate of 14 ml/hr, and the 2.0-ml fractions
were lyophilized to dryness and reconstituted in 1.0 ml of DMEM.
The activity of each fraction was determined by adding 10 ,Al directly
to quiescent endothelial cultures containing 2% (vol/vol) PPP, and
0.2 ml ofDMEM and measuring [3H]thymidine incorporation after a
36-hr incubation as described in Fig. 1. The results (open bars) are
expressed as the percent inhibition of maximal [3H]thymidine incor-
poration that was present in control culture receiving PDECM at 0.5
,g/ml plus 2% (vol/vol) PPP.
The inhibitor not only lowers the basal rate of [3H]thymi-
dine incorporation in nonstimulated cultures but also blocks
the stimulatory effects of human serum and PDECM. This
inhibition is reversible, however, and can be partially over-
come either by adding higher concentrations of PDECM or
by adding the inhibitor transiently and then removing it from
the incubation medium.
The inhibitor causes significant inhibition of porcine
endothelial cell division as well as [3H]thymidine incorpo-
ration. This finding excludes the possibility that the inhibitor
is merely acting by altering the specific activity or the
distribution of intracellular [3H]thymidine pools (12, 13).
The inhibitory effect of the PDGI that was purified through
the heparin-Sepharose step was limited to endothelium, since
it did not inhibit DNA synthesis in smooth muscle cells or
BALB/c 3T3 fibroblasts. These results suggest that the
platelets contain more than one inhibitory factor and that the
peptide we have characterized in this report is specific for
endothelium.
Other inhibitors of endothelial growth have been reported.
Two of these have been detected in crude extracts from
tissues characterized by their relative avascularity-i.e.,
cartilage (14) and vitreous (15). The chemical composition of
the cartilage inhibitor was not reported; however, the bioac-
tive vitreous material was destroyed by proteolytic enzymes.
Two other laboratories have reported that inhibitors are
released by confluent endothelial cell cultures (16, 17). One
of these substances is endothelial cell-derived heparin (17).
Our findings indicate that the bioactivity of the partially
purified inhibitor is not destroyed by incubation with hep-
arinase and, therefore, it is not a heparin type of substance.
Earlier studies have reported that crude platelet extracts
contain material that can inhibit endothelial cell replication
(3, 18, 19). Although further chemical characterization of
these factors was not reported, these reports provide further
evidence to support the existence of platelet-derived inhibi-
tors of endothelial growth. B-transforming growth factor has
been shown to inhibit DNA synthesis in ARK 2-B and BSC-1
cells (20). Since B-transforming growth factor is a peptide
contained in platelets, it is possible the inhibitor described in
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these studies is the same substance. However, B-transform-
ing growth factor is acid and heat stable and has a molecular
weight of -22,000, indicating that the two peptides have very
distinct chemical properties (20). In summary, there appear
to be several classes of substances that inhibit endothelial
growth. Definition of the exact number of compounds that fit
in each of these categories will require further purification
and structural characterization of each chemically distinct
substance.
The role of specific molecular substances derived from
platelets in controlling the rate of reendothelialization fol-
lowing injury is unknown. These findings suggest a mecha-
nism that could regulate endothelial growth following injury.
After platelet adherence, three classes of substances would
be released into the microenvironment: PDECM, PDGI, and
proteolytic enzymes. Since the inhibitor can directly block
the effects of the mitogen, it is possible that it functions
locally to regulate the expression of its effects. The suscep-
tibility ofthe inhibitor to proteolysis suggests that proteolytic
enzymes in the microenvironment could have a direct effect
on its available concentration and, thereby, indirectly mod-
ulate growth at discrete sites. This conclusion is strengthened
by data from other laboratories that have shown that
proteases present in the microenvironment after wounding,
such as thrombin, are mitogenic for cultured endothelial cells
(21, 22). Substantiation of this hypothesis will require puri-
fication of each factor to homogeneity and detailed analysis
of the effects of proteolytic enzymes that are present in the
injured vessel wall microenvironment.
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